Please assess the completion status of the following clinical trial:

Trial Title: Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Chronic rejection~1. Bronchiolitis obliterans diagnosed by bronchiolitis obliterans syndrome and \> 20% decline from the individual patient's best FEV1 is observed~2. Recipient of a double or single lung transplant~3. Receiving immunosuppressive treatment according to institutional standards~Exclusion criteria:~1. Active invasive bacterial, viral or fungal infection~2. Current mechanical ventilation~3. Pregnant or breast-feeding woman~4. Known hypersensitivity to cyclosporine A~5. Serum creatinine value of more than 265 μmol/L (3 mg/dL) or chronic dialysis~6. Receipt of an investigational drug as part of a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Aerosol Cyclosporine (Type: EXPERIMENTAL): Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
- Conventional oral immune suppression (Type: ACTIVE_COMPARATOR): Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well.

Based on this trial design, predict the completion outcome and termination type (if applicable).